Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Imatinib in KIT-negative Systemic Mastocytosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Hospital Virgen de la Salud.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
LUIS ESCRIBANO, Hospital Virgen de la Salud Identifier:
First received: February 16, 2011
Last updated: March 29, 2012
Last verified: March 2012

The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Imatinib Mesylate therapy in patients with systemic mastocytosis lacking KIT mutations.

Condition Intervention Phase
Systemic Mastocytosis
Drug: Imatinib Mesylate
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Imatinib Mesylate Therapy in Systemic Mastocytosis Patients Lacking KIT Mutations

Resource links provided by NLM:

Further study details as provided by Hospital Virgen de la Salud:

Primary Outcome Measures:
  • To evaluate the effect of Imatinib Mesylate on clinical mastocytosis-related features: skin lesions, mast-cell related symptoms (pruritus, flushing, gastrointestinal symptoms, anaphylaxis), organomegalies/adenopathies and bone alterations. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Clinical parameters are evaluated before and after therapy by macroscopic and histological skin examination, the record of frequency and severity of mast cell-mediators release symptoms, abdominal ultrasonography and x-ray survey.

Secondary Outcome Measures:
  • To evaluate the effect of Imatinib Mesylate on the grade of bone marrow mast cells infiltration as assessed by bone marrow histology and cytology, and flow cytometry performed on highly-purified bone marrow mast cells. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • To investigate changes after Imatinib Mesilate therapy in mast cell clonality as assessed by the HUMARA test performed on highly-purified bone marrow mast cells. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • To determine the effect of Imatinib Mesylate therapy on serum tryptase levels. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • To determine the effect of Imatinib Mesylate therapy in the psychological impact of the disease and the quality of life of patients as assessed by the Dermatology Life Quality Index . [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: January 2011
Estimated Study Completion Date: June 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Imatinib Mesylate
    • In patients without B or C findings and without biological progression: 300 mg/24 h p.o during one year or until progression/unacceptable toxicity.
    • In patients with B or C findings or biological progression: 300 mg/24 h p.o for two weeks and then 400 mg/24 h p.o for a total of one year of therapy, or until progression/unacceptable toxicity.
    Other Names:
    • Gleevec
    • STI571
Detailed Description:

In vitro studies have proven that imatinib inhibits wild type Kit (wtKit) and suppresses proliferation of the HMC-1V560G cell line, while it is ineffective on inhibiting the growth of HMC-1V560G, D816V cells. Apart from wtKit, Kit molecules carrying mutations in the extracellular, transmembrane and juxtamembrane domains, such as V560G, F522C and K509I, remain sensitive to imatinib. In contrast, several experiments have provided compelling evidence regarding the resistance against the growth-inhibitory effects of imatinib on cells carrying the D816V KIT mutation. As a consequence, sensitive and specific methods should be used in order to avoid "false" KIT mutation-negative cases and, for that purpose, mainly in cases with low bone marrow mast cell numbers, mutational studies should be performed using highly purified bone marrow mast cells by means of Facs sorting systems better than whole bone marrow, unsorted mononuclear cell fraction or mononuclear cell fraction pre-enriched using magnetic beads conjugated with anti-CD25 monoclonal antibody. In the present study mutational studies were performed in all cases in purified bone marrow mast cells (purity > 97%) using a FACSaria system (Becton-Dickinson Biosciences) as previously described.

Patients without B or C findings according to the World Health Organization, and without features of biological progression of the disease receive oral Imatinib Mesylate 300 mg daily for up to 12 months or until clinical progression/unacceptable toxicity. Patients with B or C findings or biological progression initially receive oral Imatinib Mesylate 300 mg daily for two weeks; then, dose is increased up to 400 mg/day except in patients who develop hematological or any other dose-limiting toxicity.

Biological progression is defined as the presence of at least one of the following features: i) increased serum tryptase levels > 200 ng/mL, ii) diffuse bone sclerosis, iii) patchy sclerosis with osteolysis and increased risk of bone fracture or significant bone pain, and, iv) organomegalies or lymph node enlargement due to mastocytosis.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age older than 18 years.
  • Diagnosis of systemic mastocytosis in the absence of c-kit mutation.
  • ECOG ≤ 3.
  • Signed informed consent.

Exclusion Criteria:

  • Previous therapy with a tyrosin kinase inhibitor.
  • Positive antibodies against HIV or active viral hepatitis.
  • Impaired liver function (total bilirubin ≥ 2.0 mg/dl, AST or ALT > 3 x upper limit of normal).
  • Impaired renal function (≥ 2.0 mg/dL).
  • Grade III-IV cytopenias not related to mastocytosis.
  • Severe cardiopathy (grade III/IV of NYHA, or left ventricular ejection fraction < 50%).
  • Pregnancy or breastfeeding.
  • Female patients who do not use contraceptive methods.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01297777

Instituto de Estudios de Mastocitosis de Castilla La Mancha; Hospital Virgen del Valle
Toledo, Spain, 45071
Sponsors and Collaborators
Hospital Virgen de la Salud
Principal Investigator: Luis Escribano, MD, PhD Instituto de Estudios de Mastocitosis de Castilla La Mancha
  More Information

Additional Information:

Responsible Party: LUIS ESCRIBANO, Director Instituto de Estudios de Mastocitosis de Castilla La Mancha, Hospital Virgen de la Salud Identifier: NCT01297777     History of Changes
Other Study ID Numbers: EudraCT 2010-019189-94
Study First Received: February 16, 2011
Last Updated: March 29, 2012
Health Authority: Spain: Ministry of Health

Keywords provided by Hospital Virgen de la Salud:
Mast cell
Mast cell disease

Additional relevant MeSH terms:
Mastocytosis, Systemic
Urticaria Pigmentosa
Mastocytosis, Cutaneous
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Pigmentation Disorders
Skin Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses processed this record on November 24, 2014